NASDAQ:OPRX - Get Free Report ) is set to announce its earnings results after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link .
Get OptimizeRx alerts:
Sign Up
OptimizeRx (NASDAQ:OPRX - Get Free Report ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $0.11 earnings per share for the quarter. OptimizeRx had a negative net margin of 24.56% and a negative return on equity of 7.72%. The business had revenue of $28.37 million during the quarter. On average, analysts expect OptimizeRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
OptimizeRx Trading Up 1.6 % Shares of OPRX stock traded up $0.17 during trading hours on Tuesday, hitting $10.79. The company had a trading volume of 72,445 shares, compared to its average volume of 127,857. The stock has a market capitalization of $196.16 million, a PE ratio of -10.51 and a beta of 1.05. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.04 and a quick ratio of 3.04. OptimizeRx has a fifty-two week low of $6.92 and a fifty-two week high of $16.65. The company's fifty day moving average is $12.02 and its 200 day moving average is $12.18.
Analyst Upgrades and Downgrades OPRX has been the subject of a number of research reports. Stifel Nicolaus reaffirmed a "buy" rating and issued a $13.00 price objective on shares of OptimizeRx in a research note on Monday, April 1st. JMP Securities reiterated a "market outperform" rating and set a $15.00 price target on shares of OptimizeRx in a research note on Tuesday, April 16th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $17.00 price objective on shares of OptimizeRx in a research note on Monday, April 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, OptimizeRx presently has a consensus rating of "Moderate Buy" and an average price target of $15.86.
Check Out Our Latest Report on OPRX
OptimizeRx Company Profile (
Get Free Report )
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.
Read More
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
